Immunosuppressive Medications for Participants in ITN005CT
Principal Investigator
Daniel Brennan | Washington University in St. Louis | St. Louis, MO
Locations
University of Miami | Miami,FL
Washington University at St. Louis | St. Louis,MO
Massachusetts General Hospital | Boston,MA
Study Code
ITN040CT
Study Status
Complete
Abstract
This study is for participants who have received up to three islet cell infusions as a previous participant in the ITN005CT study. Study participants will receive a maintenance immunosuppressive treatment regimen consisting of a combination of orally administered drugs (tacrolimus (Prograf®), sirolimus (Rapamune®), mycophenolate mofetil (MMF, Cellcept®), and/or mycophenolic acid (MPA, Myfortic®).) This protocol provides a way to supply these immunosuppressive medications to subjects whose islets continue to function and make C-peptide.
Qualification
Articles
Brennan DC, Kopetskie HA, Sayre PH, Alejandro R, Cagliero E, Shapiro AM, Goldstein JS, DesMarais MR, Booher S, Bianchine PJ (2016). Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States. Am J Transplant, 16(2), 509-17. https://doi.org/10.1111/ajt.13458 PMID: 26433206.
